Evidence map›Paper›PMID 41990746›Full record

ArticleCell metabolism2026

Mitochondrial metabolism regulates the immunogenic responsiveness of dendritic cells.

Ignacio Heras-Murillo, Diego Mañanes, Josep Calafell-Segura, Adrián Belinchón García, Clara Borràs-Eroles, Pablo Munné, Annalaura Mastrangelo, Sarai Martínez-Cano, Pablo Hernansanz-Agustín, María A Zuriaga and 8 more

Erratum issuedAbstract read
In one paragraph

Article in Cell metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Ignacio Heras-MurilloCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Diego MañanesCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; Universidad Autónoma de Madrid, Escuela de Doctorado, Madrid, Spain.
Josep Calafell-SeguraEpigenetics and Immune Disease Group, Josep Carreras Leukaemia Research Institute (IJC), 08916 Barcelona, Spain.
Adrián Belinchón GarcíaCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Clara Borràs-ErolesInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Pablo MunnéCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; Universidad Autónoma de Madrid, Escuela de Doctorado, Madrid, Spain.
Annalaura MastrangeloCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
Sarai Martínez-CanoCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; Inmunotek S.L., Alcalá de Henares, Spain.
Pablo Hernansanz-AgustínCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; Centro de Neurociencias Cajal (CNC), Alcalá de Henares, Spain.
María A ZuriagaCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain.
José J FusterCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; CIBER en Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain.
Marten SziborFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Cardiothoracic Surgery, Center for Sepsis Control and Care (CSCC), Jena University Hospital, Jena, Germany.
Ignacio MeleroProgram of Immunology and Immunotherapy, CIMA Universidad de Navarra, Pamplona, Spain; Nuffield Department of Medicine, University of Oxford, Oxford, UK; Navarra Institute for Health Research (IDISNA), CIBERONC, Pamplona, Spain.
José Antonio EnríquezCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; Centro de Investigaciones Biomédicas en Red en Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain.
Navdeep S ChandelDepartment of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Chan Zuckerberg Biohub, Chicago, IL 60642, USA.
Esteban BallestarEpigenetics and Immune Disease Group, Josep Carreras Leukaemia Research Institute (IJC), 08916 Barcelona, Spain; Epigenetics in Inflammatory and Metabolic Diseases Laboratory, Health Science Center (HSC), East China Normal University (ECNU), Shanghai 200241, China.
Stefanie K WculekCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. Electronic address: stefanie.wculek@irbbarcelona.org.
David SanchoCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain. Electronic address: dsancho@cnic.es.

Funding

Mitochondrial Metabolism and CancerR01CA290678 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI NAVDEEP S CHANDEL · 2024 to 2026
$3.0M
NCI NIH HHS R01 CA290678
6 · The paper itself

Abstract

Activation of conventional dendritic cells (cDCs) favors increased glycolysis-driven lactic fermentation, while oxidative phosphorylation (OXPHOS) links to tolerance. Here, selective targeting of the mitochondrial electron transport chain (ETC) in cDCs uncovers a critical role for OXPHOS in regulating their immunogenicity. Disruption of ETC complex III dampens adjuvant-triggered primary human and mouse cDC1 activation and their capability to prime T cells for anti-cancer immunity, while it has a milder effect on cDC2s. Mechanistically, complex III impairment in cDC1s leads to a dysregulated redox and metabolite balance, altering DNA methylation of PU.1 and activator-protein-1 (AP-1) binding regions. These epigenetic changes hinder the rapid induction of immediate-early stimulus-induced genes in cDC1s upon stimulation. The reduced immunogenic responsiveness of ETC-impaired cDC1s can be rescued by ectopic expression of alternative oxidase and phenocopied by Tet2 deficiency. Our findings reveal that electron flow through the ETC maintains a poised activation state in cDC1s, essential for effective anti-tumor immunity.

Indexed as

Dendritic CellsMitochondriaAnimalsDioxygenasesDNA-Binding ProteinsDNA MethylationHumansMiceMice, Inbred C57BLOxidative PhosphorylationProto-Oncogene ProteinsDioxygenasesDNA-Binding ProteinsProto-Oncogene ProteinsTet2 protein, mousedendritic cellsDNA methylationelectron transport chainimmunitymetabolitesmitochondriaredox balance

Identifiers

PMID41990746
PMCPMC13396705

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.